{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:33:05Z","timestamp":1790134385297,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract\u00a0\u00a0\u00a0<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hypophosphatasia (HPP) is a rare, dento-osseous disorder caused by impaired activity of tissue non-specific alkaline phosphatase (TNSALP), a key enzyme in tissue mineralization. This review provides a clinical perspective on the current medical treatment of both children and adults with HPP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Dental problems, rickets in children, and osteomalacia in adults are common in HPP. However, disease manifestations in individual patients are exceptionally variable. Recent studies broadened our understanding of HPP symptoms. For example, data showed behavioral health challenges in HPP children, and a large, real-world data set from the Global HPP Registry demonstrated that HPP adults regardless of the time of disease onset exhibit significant disease burden and are broadly affected by non-skeletal impairments, such as pain and chronic fatigue. Treatment for HPP relies on the enzyme replacement asfotase alfa. Small, mostly pediatric trials initially established dosing, safety and efficacy of asfotase alfa, and latest data corroborated the long-term safety and efficacy in both children and pediatric-onset adults. Data from several recent observational studies, including the Global HPP Registry, underscored that asfotase alfa improves physical functions, non-skeletal symptoms such as pain, and quality-of-life (QoL) in adults irrespective of age-of-onset. Clinical use of asfotase alfa is based on prescribing information and evidence-based consensus guidelines. However, recommendations for initiation of therapy are just emerging. Alternatives to asfotase alfa remain limited, but a derivative, efzimfotase alfa, currently undergoes clinical testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Studies in larger HPP patient populations suggest efficacy of enzyme replacement therapy independent of patient age and time of disease onset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11914-025-00906-5","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:20:20Z","timestamp":1742296820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-9138","authenticated-orcid":false,"given":"Kathryn McCrystal","family":"Dahir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1783-4605","authenticated-orcid":false,"given":"Nancy S.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"4","key":"906_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12(4):233\u201346.","journal-title":"Nat Rev Endocrinol"},{"key":"906_CR2","doi-asserted-by":"publisher","first-page":"116947","DOI":"10.1016\/j.bone.2023.116947","volume":"178","author":"MR Farman","year":"2024","unstructured":"Farman MR, et al. The Global ALPL gene variant classification project: Dedicated to deciphering variants. Bone. 2024;178:116947.","journal-title":"Bone"},{"key":"906_CR3","volume-title":"B-Complex Vitamins - Sources, Intakes and Novel Applications","author":"HH Al-Shekaili","year":"2021","unstructured":"Al-Shekaili HH, van Karnebeek C, Leavitt BR. Vitamin B6 and Related Inborn Errors of Metabolism. In: LeBlanc JG, editor. B-Complex Vitamins - Sources, Intakes and Novel Applications. Intechopen; 2021."},{"issue":"5S2","key":"906_CR4","doi-asserted-by":"publisher","first-page":"5S85","DOI":"10.1016\/S0929-693X(18)30021-6","volume":"24","author":"C Fonta","year":"2017","unstructured":"Fonta C, Salles JP. Neuromuscular features of hypophosphatasia. Arch Pediatr. 2017;24(5S2):5S85\u20138.","journal-title":"Arch Pediatr"},{"issue":"3","key":"906_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00198-023-06844-1","volume":"35","author":"AA Khan","year":"2024","unstructured":"Khan AA, et al. Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int. 2024;35(3):431\u20138.","journal-title":"Osteoporos Int"},{"issue":"2","key":"906_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41431-020-00732-6","volume":"29","author":"E Mornet","year":"2021","unstructured":"Mornet E, et al. Hypophosphatasia: a genetic-based nosology and new insights in genotype-phenotype correlation. Eur J Hum Genet. 2021;29(2):289\u201399.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"906_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13023-021-01722-7","volume":"16","author":"EI Pierpont","year":"2021","unstructured":"Pierpont EI, et al. Impact of pediatric hypophosphatasia on behavioral health and quality of life. Orphanet J Rare Dis. 2021;16(1):80.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"906_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-020-01500-x","volume":"15","author":"M Vogt","year":"2020","unstructured":"Vogt M, et al. Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children. Orphanet J Rare Dis. 2020;15(1):212.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"906_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000531865","volume":"97","author":"GA Martos-Moreno","year":"2024","unstructured":"Martos-Moreno GA, et al. Clinical Profiles of Children with Hypophosphatasia prior to Treatment with Enzyme Replacement Therapy: An Observational Analysis from the Global HPP Registry. Horm Res Paediatr. 2024;97(3):233\u201342.","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"906_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13023-022-02393-8","volume":"17","author":"KM Dahir","year":"2022","unstructured":"Dahir KM, et al. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022;17(1):277.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"906_CR11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/jbmr.4130","volume":"35","author":"L Seefried","year":"2020","unstructured":"Seefried L, et al. Burden of illness in adults with hypophosphatasia: data from the global hypophosphatasia patient registry. J Bone Miner Res. 2020;35(11):2171\u20138.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"906_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-024-03048-6","volume":"19","author":"PS Kishnani","year":"2024","unstructured":"Kishnani PS, et al. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Orphanet J Rare Dis. 2024;19(1):109.","journal-title":"Orphanet J Rare Dis"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","volume":"75","author":"MP Whyte","year":"2015","unstructured":"Whyte MP, et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone. 2015;75:229\u201339.","journal-title":"Bone"},{"key":"906_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2018.01.022","volume":"110","author":"MP Whyte","year":"2018","unstructured":"Whyte MP, et al. Hypophosphatasia: Biochemical hallmarks validate the expanded pediatric clinical nosology. Bone. 2018;110:96\u2013106.","journal-title":"Bone"},{"issue":"1\u20132","key":"906_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","volume":"122","author":"PS Kishnani","year":"2017","unstructured":"Kishnani PS, et al. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017;122(1\u20132):4\u201317.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"906_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.11138\/ccmbm\/2017.14.1.230","volume":"14","author":"F Conti","year":"2017","unstructured":"Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab. 2017;14(2):230\u20134.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"1","key":"906_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-023-06843-2","volume":"35","author":"E Rush","year":"2024","unstructured":"Rush E, et al. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP international working group. Osteoporos Int. 2024;35(1):1\u201310.","journal-title":"Osteoporos Int"},{"issue":"6","key":"906_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/jbmr\/zjae098","volume":"39","author":"MP Whyte","year":"2024","unstructured":"Whyte MP, et al. Pediatric hypophosphatasia: avoid diagnosis missteps! J Bone Miner Res. 2024;39(6):655\u201360.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"906_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/archpedi.1948.02030020840003","volume":"75","author":"JC Rathbun","year":"1948","unstructured":"Rathbun JC. 1948 Hypophosphatasia; a new developmental anomaly. Am J Dis Child (1911). 1948;75(6):822\u201331.","journal-title":"Am J Dis Child (1911)"},{"issue":"6","key":"906_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1359\/jbmr.071213","volume":"23","author":"JL Millan","year":"2008","unstructured":"Millan JL, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008;23(6):777\u201387.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"906_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","volume":"98","author":"JL Millan","year":"2016","unstructured":"Millan JL, Whyte MP. Alkaline Phosphatase and Hypophosphatasia. Calcif Tissue Int. 2016;98(4):398\u2013416.","journal-title":"Calcif Tissue Int"},{"key":"906_CR22","unstructured":"Alexion Pharmaceuticals I.\u00a0STRENSIQ Prescribing Information. 2024, in https:\/\/alexion.com\/documents\/strensiq_uspi.pdf. Accessed 3 Mar 2025."},{"issue":"10","key":"906_CR23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"906_CR24","doi-asserted-by":"publisher","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","volume":"1","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight. 2016;1(9):e85971.","journal-title":"JCI Insight"},{"key":"906_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","volume":"121","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149\u201362.","journal-title":"Bone"},{"key":"906_CR26","doi-asserted-by":"publisher","first-page":"101617","DOI":"10.1016\/j.bonr.2022.101617","volume":"17","author":"C Rockman-Greenberg","year":"2022","unstructured":"Rockman-Greenberg C, et al. Impact of discontinuing 5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: A case series. Bone Rep. 2022;17:101617.","journal-title":"Bone Rep"},{"issue":"7","key":"906_CR27","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/jc.2018-02335","volume":"104","author":"CE Hofmann","year":"2019","unstructured":"Hofmann CE, et al. Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study. J Clin Endocrinol Metab. 2019;104(7):2735\u201347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"906_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7(2):93\u2013105.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"906_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/jc.2015-3462","volume":"101","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"906_CR30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/jcph.1870","volume":"61","author":"WJ Pan","year":"2021","unstructured":"Pan WJ, et al. Pharmacokinetics of asfotase alfa in adult patients with pediatric-onset hypophosphatasia. J Clin Pharmacol. 2021;61(10):1334\u201343.","journal-title":"J Clin Pharmacol"},{"key":"906_CR31","doi-asserted-by":"publisher","first-page":"115664","DOI":"10.1016\/j.bone.2020.115664","volume":"142","author":"L Seefried","year":"2021","unstructured":"Seefried L, et al. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone. 2021;142:115664.","journal-title":"Bone"},{"key":"906_CR32","doi-asserted-by":"publisher","first-page":"116856","DOI":"10.1016\/j.bone.2023.116856","volume":"175","author":"L Seefried","year":"2023","unstructured":"Seefried L, et al. Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment. Bone. 2023;175:116856.","journal-title":"Bone"},{"issue":"12","key":"906_CR33","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00198-021-06025-y","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, et al. Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa. Osteoporos Int. 2021;32(12):2505\u201313.","journal-title":"Osteoporos Int"},{"issue":"9","key":"906_CR34","doi-asserted-by":"publisher","first-page":"e10395","DOI":"10.1002\/jbm4.10395","volume":"4","author":"F Genest","year":"2020","unstructured":"Genest F, et al. Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. JBMR Plus. 2020;4(9):e10395.","journal-title":"JBMR Plus"},{"issue":"10","key":"906_CR35","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/jbmr\/zjae128","volume":"39","author":"KM Dahir","year":"2024","unstructured":"Dahir KM, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Efzimfotase Alfa, a Second-generation Enzyme Replacement Therapy: Phase 1, Dose-escalation Study in Adults with Hypophosphatasia. J Bone Miner Res. 2024;39(10):1412\u201323.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"906_CR36","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40618-023-02256-4","volume":"47","author":"KM Dahir","year":"2024","unstructured":"Dahir KM, et al. A Delphi panel to build consensus on assessing disease severity and disease progression in adult patients with hypophosphatasia in the United States. J Endocrinol Invest. 2024;47(6):1487\u201397.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"906_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","volume":"20","author":"W Hogler","year":"2019","unstructured":"Hogler W, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019;20(1):80.","journal-title":"BMC Musculoskelet Disord"},{"key":"906_CR38","doi-asserted-by":"publisher","unstructured":"Montero-Lopez R, Farman MR, H\u00f6gler F, Saraff V, H\u00f6gler W. Challenges in hypophosphatasia: suspicion, diagnosis, genetics, management, and follow-up. Horm Res Paediatr.\u00a02024.\u00a0https:\/\/doi.org\/10.1159\/000540692.","DOI":"10.1159\/000540692"},{"key":"906_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bone.2019.02.025","volume":"122","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, et al. No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Bone. 2019;122:231\u20136.","journal-title":"Bone"},{"issue":"8","key":"906_CR40","doi-asserted-by":"publisher","first-page":"ziae062","DOI":"10.1093\/jbmrpl\/ziae062","volume":"8","author":"KM Dahir","year":"2024","unstructured":"Dahir KM, et al. Improvement in quality of life after asfotase alfa treatment in adults with pediatric-onset hypophosphatasia: data from 5 patient-reported outcome measures. JBMR Plus. 2024;8(8):ziae062.","journal-title":"JBMR Plus"},{"key":"906_CR41","unstructured":"Dahir K, Dahir S, Black M, Campbell E, Rockman-Greenberg C. Towards establishing clinically useful treatment guidelines for ERT in HPP patients) understanding the impact of discontinuing enzyme replacement therapy in adult patients with hypophosphatasia. J Bone Miner Res. 2023;38 (Suppl 2). Available at 2023 Abstracts - American Society for Bone and Mineral Research."},{"key":"906_CR42","doi-asserted-by":"publisher","first-page":"116504","DOI":"10.1016\/j.bone.2022.116504","volume":"163","author":"Z Shajani-Yi","year":"2022","unstructured":"Shajani-Yi Z, et al. Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults. Bone. 2022;163:116504.","journal-title":"Bone"},{"key":"906_CR43","doi-asserted-by":"publisher","first-page":"104915","DOI":"10.1016\/j.ejmg.2024.104915","volume":"68","author":"Z Zervou","year":"2024","unstructured":"Zervou Z, et al. Impressive clinical improvement and disappearance of neuropathic pain in an adult patient with hypophosphatasia treated with asfotase alfa. Eur J Med Genet. 2024;68:104915.","journal-title":"Eur J Med Genet"},{"issue":"1","key":"906_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33176\/AACB-19-00031","volume":"41","author":"JP Salles","year":"2020","unstructured":"Salles JP. Hypophosphatasia: biological and clinical aspects, avenues for therapy. Clin Biochem Rev. 2020;41(1):13\u201327.","journal-title":"Clin Biochem Rev"},{"key":"906_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","volume":"102","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: An overview For 2017. Bone. 2017;102:15\u201325.","journal-title":"Bone"},{"key":"906_CR46","doi-asserted-by":"publisher","first-page":"115413","DOI":"10.1016\/j.bone.2020.115413","volume":"137","author":"JH Simmons","year":"2020","unstructured":"Simmons JH, et al. Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: A pooled post hoc analysis of asfotase alfa clinical trial data. Bone. 2020;137:115413.","journal-title":"Bone"},{"key":"906_CR47","doi-asserted-by":"publisher","first-page":"101715","DOI":"10.1016\/j.bonr.2023.101715","volume":"19","author":"JM Colazo","year":"2023","unstructured":"Colazo JM, et al. Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years. Bone Rep. 2023;19:101715.","journal-title":"Bone Rep"},{"issue":"2","key":"906_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/antib7020019","volume":"7","author":"KP Pratt","year":"2018","unstructured":"Pratt KP. Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity. Antibodies (Basel). 2018;7(2):19.","journal-title":"Antibodies (Basel)"},{"key":"906_CR49","unstructured":"Voegtli WC, Baranello M, Bouchard K (2021) Alkaline phosphatase polypeptides and methods of use thereof\u00a0 US 2021\/0169994 A1 United States US020210169994A120210610."},{"issue":"1","key":"906_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/ijms20010083","volume":"20","author":"G Russow","year":"2018","unstructured":"Russow G, et al. Anabolic therapies in osteoporosis and bone regeneration. Int J Mol Sci. 2018;20(1):83.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"906_CR51","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1210\/jc.2006-1902","volume":"92","author":"MP Whyte","year":"2007","unstructured":"Whyte MP, Mumm S, Deal C. Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab. 2007;92(4):1203\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"906_CR52","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4158\/EP15890.OR","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, et al. Adult hypophosphatasia treated with teriparatide: report of 2 patients and review of the literature. Endocr Pract. 2016;22(8):941\u201350.","journal-title":"Endocr Pract"},{"issue":"8","key":"906_CR53","doi-asserted-by":"publisher","first-page":"e10215","DOI":"10.1002\/jbm4.10215","volume":"3","author":"T Schmidt","year":"2019","unstructured":"Schmidt T, et al. Outcome of teriparatide treatment on fracture healing complications and symptomatic bone marrow edema in four adult patients with hypophosphatasia. JBMR Plus. 2019;3(8):e10215.","journal-title":"JBMR Plus"},{"issue":"3","key":"906_CR54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jbspin.2017.12.001","volume":"85","author":"M Righetti","year":"2018","unstructured":"Righetti M, et al. Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures. Joint Bone Spine. 2018;85(3):365\u20137.","journal-title":"Joint Bone Spine"},{"issue":"12","key":"906_CR55","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1210\/jc.2010-1168","volume":"95","author":"C Schalin-Jantti","year":"2010","unstructured":"Schalin-Jantti C, et al. Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia. J Clin Endocrinol Metab. 2010;95(12):5174\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"906_CR56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00223-011-9562-5","volume":"90","author":"M Laroche","year":"2012","unstructured":"Laroche M. Failure of teriparatide in treatment of bone complications of adult hypophosphatasia. Calcif Tissue Int. 2012;90(3):250.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"906_CR57","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1210\/jc.2009-1965","volume":"95","author":"C Gagnon","year":"2010","unstructured":"Gagnon C, et al. Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J Clin Endocrinol Metab. 2010;95(3):1007\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"906_CR58","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1172\/JCI83731","volume":"127","author":"L Seefried","year":"2017","unstructured":"Seefried L, et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest. 2017;127(6):2148\u201358.","journal-title":"J Clin Invest"},{"key":"906_CR59","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.tcr.2024.101077","volume":"53","author":"PE Schwab","year":"2024","unstructured":"Schwab PE, Dessain A, Milby J. Monoclonal antibody anti-sclerostin for treatment of pelvic insufficiency fractures in adult hypophosphatasia: A case report. Trauma Case Rep. 2024;53:101077.","journal-title":"Trauma Case Rep"},{"issue":"11","key":"906_CR60","doi-asserted-by":"publisher","first-page":"104856","DOI":"10.1016\/j.ejmg.2023.104856","volume":"66","author":"N Fratzl-Zelman","year":"2023","unstructured":"Fratzl-Zelman N, et al. Combination of osteogenesis imperfecta and hypophosphatasia in three children with multiple fractures, low bone mass and severe osteomalacia, a challenge for therapeutic management. Eur J Med Genet. 2023;66(11):104856.","journal-title":"Eur J Med Genet"},{"issue":"9","key":"906_CR61","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/jbmr.4382","volume":"36","author":"Y Kinoshita","year":"2021","unstructured":"Kinoshita Y, et al. Gene Therapy Using Adeno-Associated Virus Serotype 8 Encoding TNAP-D(10) Improves the Skeletal and Dentoalveolar Phenotypes in Alpl(-\/-) Mice. J Bone Miner Res. 2021;36(9):1835\u201349.","journal-title":"J Bone Miner Res"},{"key":"906_CR62","unstructured":"Musial-Siwek M et al. CRISPR\/Cas9-based precision B cell gene engineering coupled with artificial intelligenceguided protein design produces active tissue nonspecific alkaline phosphatase for the treatment of hypophosphatasia, in ASBMR annual meeting. 2024: Toronto, Canada. Available at CRISPR\/Cas9-Based Precision B cell gene engineering coupled with artificial intelligence-guided protein design produces active tissue nonspecific alkaline phosphatase for the treatment of hypophosphatasia."}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-025-00906-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:39:03Z","timestamp":1768473543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-025-00906-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s11914-025-00906-5","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"17 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KD is a clinical trial investigator for Alexion, Regeneron, Ultragenyx, Kyowa Kirin, Sanofi. ND serves as a clinical trial investigator for Alexion and Ultragenyx, and as consultant and speaker board member for Alexion, Kyowa Kirin, and Biomarin.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both authors are clinical trial investigators for Alexion so this must be disclosed. See disclosures in the manuscript. However this review article was not funded by Alexion or any other organization.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14"}}